Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation develops and commercializes ophthalmic pharmaceutical and medical technology products for glaucoma, corneal disorders, and retinal diseases. News about Glaukos regularly covers financial results, global commercial execution, and updates for its dropless platform technologies, including iDose TR for sustained intracameral glaucoma drug delivery and Epioxa for corneal cross-linking in keratoconus.
Recurring company developments include FDA labeling actions for iDose TR, CMS coding and commercial availability updates for Epioxa, scientific presentations in ophthalmology, and quarterly sales trends across its glaucoma franchise. Company background also includes Micro-Invasive Glaucoma Surgery products such as iStent, iStent inject W, and iStent infinite, along with a pipeline aimed at chronic eye diseases.
Glaukos (NYSE:GKOS) announced management participation in several investor conferences in May and June 2026, including events hosted by Stifel, William Blair, Jefferies, and Truist.
Live and archived webcasts, where available, will be accessible through the Investors section of the Glaukos website.
Glaukos (NYSE: GKOS) reported Q1 2026 net sales of $150.6 million, up 41% year-over-year (39% constant currency). Glaucoma sales were $129.3 million; U.S. Glaucoma sales were $93.5 million. Gross margin ~78% (non-GAAP ~84%). Raised 2026 revenue guidance to $620–$635 million. Cash and equivalents approx. $280.5 million; no debt.
SG&A rose 32% and R&D rose 36%; GAAP net loss was $19.8 million, non-GAAP net loss $10.4 million.
Glaukos (NYSE: GKOS) published its 2025 Sustainability Report highlighting progress on corporate sustainability, patient access, governance, and operations.
Key metrics: $22 million in product donations to date, ~870 volunteer hours, outreach to ~15,000 patients, ~14,000 keratoconus patients served, FDA approval for Epioxa, groundbroken for a new Huntsville R&D and manufacturing facility, 100% cybersecurity training completion, and external limited assurance of GHG disclosures.
Glaukos (NYSE: GKOS) received a permanent HCPCS J-code J2789 for Epioxa, effective July 1, 2026. The company says the product-specific code should streamline reporting, billing, and payment by U.S. payers over time, supporting market access and the planned commercial launch for keratoconus treatment.
Epioxa is described as an incision-free, oxygen-enriched topical therapy bioactivated by UV light that avoids epithelial removal and aims to reduce pain and recovery versus traditional cross-linking.
Glaukos (NYSE: GKOS) will release first quarter 2026 financial results after the market close on April 29, 2026. Management will host a conference call and simultaneous webcast on April 29 at 1:30 p.m. PT / 4:30 p.m. ET.
Live webcast access is available at http://investors.glaukos.com. U.S. dial-in is 800-715-9871, international 646-307-1963, Conference ID 1333241. A replay will be archived on the company website after the call.
Glaukos (NYSE:GKOS) will present multiple scientific abstracts and exhibit at the ASCRS Annual Meeting, April 10–13, 2026, in Washington, D.C. The company will staff booth #407 and sponsor an educational symposium introducing Epioxa on April 10, 2026, from 12:00–1:00 p.m. ET.
Presentations cover glaucoma and corneal health, including outcomes for trabecular micro-bypass stents and travoprost intracameral implants, plus posters on corneal cross-linking and device safety.
Glaukos (NYSE: GKOS) announced commercial availability of Epioxa on March 19, 2026, the first FDA‑approved, incision‑free topical drug therapy for keratoconus.
Epioxa is an oxygen‑ and light‑catalyzed topical corneal cross‑linking treatment intended to reduce pain and recovery time versus epithelium‑removing procedures. Orders are available directly from Glaukos and via specialty distributors. The company said it will expand patient awareness, access programs, and financial assistance to address underdiagnosis and undertreatment.
Glaukos (NYSE:GKOS) reported record Q4 2025 net sales of $143.1M (+36% YoY) and full-year 2025 net sales of $507.4M (+32% YoY). The company recorded a one-time $112.9M impairment tied to an acquired intangible asset, driving a GAAP net loss of $187.7M for 2025. Glaukos ended Q4 with $282.6M in cash and no debt, and reaffirmed 2026 net sales guidance of $600M–$620M.
Non-GAAP gross margin remained strong at ~84%, while non-GAAP operating and net losses narrowed versus 2024.
Glaukos (NYSE:GKOS) announced U.S. FDA approval of an NDA labeling supplement dated January 28, 2026 permitting re-administration of iDose TR under a repeat treatment protocol.
The approval follows Glaukos' 2025 supplement and is supported by clinical evidence showing no clinically significant corneal endothelial cell loss through three years and a safe, well-tolerated second administration over 12 months.
Glaukos (NYSE: GKOS) will release its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Management will discuss results in a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 17, 2026. A live webcast link will be available at the company's investor website.
To join the call dial 800-715-9871 (U.S.) or 646-307-1963 (International) and enter Conference ID 5255602. A replay will be archived on the investor website after the call.